

BLD-010

REPORTED June 28, 2026

CLIENT

NAME

Peptide Test Canada

CONTACT

PTC Operations

EMAIL

info@peptidetestcanada.ca

ADDRESS

Canada



END CUSTOMER

NAME

Quantum Peptides

EMAIL

—

PHONE

—

ADDRESS

—

§ 01

Sample Information

FOR RESEARCH PURPOSES ONLY

Sample ID:

BLD-010

Total Mass:

62.2 mg

CAS:

—

Compound:

RETA-TIRZEPATIDE

Appearance:

Lyophilized powder

Formula:

—

Report No.:

COA-2026-SC-00101

Received:

06/24/2026

Mol Weight:

—

Lot Number:

COA-2026-SC-00101

Analyzed:

06/28/2026

§ 02

Analytical Results

Qualitative and Quantitative chemical analysis by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)


PEPTIDE	EXPECTED	MEASURED		NET PEPTIDE PURITY	STATUS
Retatrutide	6.00 mg	6.07 mg	—	98.88 %	CONFIRMED
Tirzepatide	12.00 mg	11.62 mg	—	98.83 %	CONFIRMED
TOTAL PEPTIDE	18.00 mg	17.69 mg	—		

PRECURSOR [M+5H]⁵⁺

947.90 Da

Quantifier transition ● MRM

947.90 > 136.10 CE 30 V



ROLE	TRANSITION	CE
● Quantifier	947.9 > 136.1	30 V
■ Qualifier	947.9 > 110.1	35 V


Agilent Poroshell 120 EC-C18 · 2.1×100 mm · 2.7 μm · Solvent A: 0.1 % formic acid in H₂O · Solvent B: 0.1 % formic acid in Acetonitrile

PRECURSOR [M+5H]⁵⁺

963.90 Da

Quantifier transition ● MRM

963.90 > 136.10 CE 28 V



ROLE	TRANSITION	CE
● Quantifier	963.9 > 136.1	28 V
■ Qualifier	963.9 > 110.1	33 V

Agilent Poroshell 120 EC-C18 · 2.1×100 mm · 2.7 μm · Solvent A: 0.1 % formic acid in H₂O · Solvent B: 0.1 % formic acid in Acetonitrile

DISCLAIMER · RESEARCH USE ONLY

This report documents **analytical results only**. Provided for **research purposes only**; not a drug-release or quality certification. SideChain Analytics makes no representation regarding resale, clinical use, or human / veterinary administration of the material.